Valni

Valni may be available in the countries listed below.

UK matches:

• Valni XL 30mg & 60mg Prolonged Release Tablets
• Valni XL 30mg prolonged release tablets (SPC)
• Valni XL 60mg prolonged release tablets (SPC)

Ingredient matches for Valni

Nifedipine

Nifedipine is reported as an ingredient of Valni in the following countries:

• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Downpress

Downpress may be available in the countries listed below.

Ingredient matches for Downpress

Prazosin

Prazosin hydrochloride (a derivative of Prazosin) is reported as an ingredient of Downpress in the following countries:

• Japan

International Drug Name Search

Zmax

Zmax is a brand name of azithromycin, approved by the FDA in the following formulation(s):

ZMAX (azithromycin - for suspension, extended release; oral)

• 
  Manufacturer: PFIZER GLOBAL
  
  Approval date: June 10, 2005
  
  Strength(s): EQ 2GM BASE/BOT ^[RLD]

Has a generic version of Zmax been approved?

No. There is currently no therapeutically equivalent version of Zmax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zmax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Controlled-release dosage forms of Azithromycin
  Patent 6,068,859
  Issued: May 30, 2000
  Inventor(s): Curatolo; William J. & Friedman; Hylar L. & Korsmeyer; Richard W. & LeMott; Steven R.
  Assignee(s): Pfizer Inc.
  A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.
  
  Patent expiration dates:
  
  
  • May 30, 2017
    
    ✓ 
    Drug product
  
  



• 
  Azithromycin dihydrate
  Patent 6,268,489
  Issued: July 31, 2001
  Inventor(s): Allen; Douglas J. M. & Nepveux; Kevin M.
  Assignee(s): Pfizer Inc.
  Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.
  
  Patent expiration dates:
  
  
  • July 31, 2018
    
    ✓ 
    Drug substance
  
  



• 
  Azithromycin dosage forms with reduced side effects
  Patent 6,984,403
  Issued: January 10, 2006
  Inventor(s): Hagen; Timothy A. & Lo; Julian B. & Thombre; Avinash G. & Herbig; Scott M. & Appel; Leah Elizabeth & Crew; Marshall David & Friesen; Dwayne Thomas & Lyon; David Keith & McCray; Scott Baldwin & West; James Blair
  Assignee(s): Pfizer Inc.
  The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.
  
  Patent expiration dates:
  
  
  • February 14, 2024
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
    ✓ 
    Drug product
  
  



• 
  Multiparticulate crystalline drug compositions having controlled release profiles
  Patent 7,887,844
  Issued: February 15, 2011
  Inventor(s): Appel; Leah E. & Ray; Roderick J. & Lyon; David K. & West; James B. & McCray; Scott B. & Crew; Marshall D. & Friesen; Dwayne T. & Herbig; Scott M. & Lo; Julian B.
  Assignee(s): Pfizer Inc.
  A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt % of the drug in the multiparticulate is crystalline.
  
  Patent expiration dates:
  
  
  • February 14, 2024
    
    ✓ 
    Drug product
  
  

See also...

• Zmax Extended-Release Oral Suspension Consumer Information (Wolters Kluwer)
• Zmax Consumer Information (Cerner Multum)
• Zmax Advanced Consumer Information (Micromedex)
• Azithromycin Consumer Information (Drugs.com)
• Azithromycin Consumer Information (Wolters Kluwer)
• Azithromycin Extended-Release Oral Suspension Consumer Information (Wolters Kluwer)
• Azithromycin Single-Dose Packet Consumer Information (Wolters Kluwer)
• Azithromycin Suspension Consumer Information (Wolters Kluwer)
• Azithromycin Tablets Consumer Information (Wolters Kluwer)
• Azithromycin Consumer Information (Cerner Multum)
• Azithromycin Advanced Consumer Information (Micromedex)
• Azithromycin Intravenous Advanced Consumer Information (Micromedex)
• Azithromycin AHFS DI Monographs (ASHP)

Streptomycin sulfat

Streptomycin sulfat may be available in the countries listed below.

Ingredient matches for Streptomycin sulfat

Streptomycin

Streptomycin sulfate (a derivative of Streptomycin) is reported as an ingredient of Streptomycin sulfat in the following countries:

• Bosnia & Herzegowina

International Drug Name Search

Synercid

In the US, Synercid (dalfopristin/quinupristin systemic) is a member of the drug class miscellaneous antibiotics and is used to treat Bacteremia, Methicillin-Resistant Staphylococcus Aureus Infection and Skin Infection.

US matches:

• Synercid

Ingredient matches for Synercid

Dalfopristin

Dalfopristin is reported as an ingredient of Synercid in the following countries:

• Japan


• Slovakia

Dalfopristin mesilate (a derivative of Dalfopristin) is reported as an ingredient of Synercid in the following countries:

• Australia


• Czech Republic


• Ireland


• Italy


• Poland


• United Kingdom


• United States

Quinupristin

Quinupristin is reported as an ingredient of Synercid in the following countries:

• Ireland


• Japan


• Poland


• Slovakia

Quinupristin mesilate (a derivative of Quinupristin) is reported as an ingredient of Synercid in the following countries:

• Australia


• Czech Republic


• Italy


• United Kingdom


• United States

International Drug Name Search

Speciafoldine

Speciafoldine may be available in the countries listed below.

Ingredient matches for Speciafoldine

Folic Acid

Folic Acid is reported as an ingredient of Speciafoldine in the following countries:

• France

International Drug Name Search

Silidral

Silidral may be available in the countries listed below.

Ingredient matches for Silidral

Alendronic Acid

Alendronic Acid sodium trihydrate (a derivative of Alendronic Acid) is reported as an ingredient of Silidral in the following countries:

• Argentina

International Drug Name Search